Drug Profile
Tamsulosin delayed-release - Veru Healthcare
Alternative Names: Tamsulosin delayed release sachet; Tamsulosin HCL extended release; TAMSULOSIN-DRSLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Aspen Park Pharmaceuticals
- Developer Veru Healthcare
- Class Amines; Phenyl ethers; Small molecules; Sulfonamides
- Mechanism of Action Alpha-1a adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in USA (PO, Powder)
- 02 Jul 2020 Tamsulosin delayed-release is still in preclinical trial for Benign prostatic hyperplasia in USA
- 28 Feb 2020 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in USA (PO, Powder)